Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  axitinib
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991003, NCI-2016-00392, 2015-002429-20, JAVELIN RENAL 101, NCT02684006
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCA, NCI-2016-00531, NCT02667886
Axitinib and Bosutinib in Treating Patients with Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0787, NCI-2016-01188, NCT02782403
Axitinib in Treating Patients with Stage III Malignant Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI-10-55, NCI-2012-02173, WS830279, NCT01321437
Antiandrogen Therapy with or without Axitinib before Surgery in Treating Patients with Previously Untreated Prostate Cancer with Known or Suspected Lymph Node Metastasis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2015-01711, NCI-2011-02749, NCT01409200
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A041-04, NCI-2013-00667, ACE-041, NCT01727336
Axitinib in Treating Patients with Neurofibromatosis Type 2 or Progressive Vestibular Schwannomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S14-00004, NCI-2014-01039, NCT02129647
Personalized Dose of Axitinib in Treating Patients with Previously Treated Local Recurrent or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE7815, NCI-2016-00020, 15-1386, IRB# 15-1386, NCT02579811
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AGS-16C3F-15-3, NCI-2016-00404, NCT02639182
Axitinib in Treating Patients with Recurrent or Metastatic Head and Neck Cancer That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.040, NCI-2016-01064, NCT02762513
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061068, NCI-2014-00350, 2015-001724-31, NCT01999972
Axitinib in Treating Younger Patients with Recurrent or Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 17
Trial IDs: ADVL1315, NCI-2014-01093, NCT02164838
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991002, NCI-2016-00044, 2015-001137-25, Javelin Renal 100, NCT02493751
Axitinib and L-Selenomethionine in Treating Patients with Previously Treated Advanced Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201507716, NCI-2015-02235, NCT02535533
Start Over